Glenmede Trust’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Glenmede Trust’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,050	Closed	-$5K	–	2422
2020 Q3	$5K	Buy	1,050 +8	+0.8%	+$48	﹤0.01%	2111
2020 Q2	$6K	Hold	1,042	–	–	﹤0.01%	2055
2020 Q1	$6K	Hold	1,042	–	–	﹤0.01%	2636
2019 Q4	$6K	Hold	1,042	–	–	﹤0.01%	2636
2019 Q3	$14	Hold	1,042	–	–	﹤0.01%	2221
2019 Q2	$15	Hold	1,042	–	–	﹤0.01%	2199
2019 Q1	$43	Hold	1,042	–	–	﹤0.01%	1751
2018 Q4	$43	Buy	+1,042	New	+$46.9K	﹤0.01%	1661
2018 Q3	–	Sell	-1,042	Closed	-$49K	–	1894
2018 Q2	$49K	Hold	1,042	–	–	﹤0.01%	1454
2018 Q1	$55K	Hold	1,042	–	–	﹤0.01%	1592
2017 Q4	$55K	Buy	+1,042	New	+$62K	﹤0.01%	1592

Other funds holding FSTX

AVA

Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

STC

Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glenmede Trust's FSTX Position: Q4 2020 in Review

Glenmede Trust sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q4 2020, closing a stake of 1,050 shares — an estimated $5K sold.

Glenmede Trust first reported a position in FSTX in Q4 2017 and held it in 11 quarters. The position peaked at $55K in Q1 2018. 21 funds tracked by Wall St. Rank hold FSTX as of Q4 2020.

Glenmede Trust reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 1,050 F-star Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $5K.
Glenmede Trust first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2017 and held it in 11 quarters.
Glenmede Trust's F-star Therapeutics, Inc. Common Stock position peaked at $55K in Q1 2018.
21 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.